Can semaglutide lower the incidence of cardiovascular events in patients without diabetes?

Zenodo (CERN European Organization for Nuclear Research) 2026 Open access

Read full text
Authors: Tripdatabase
DOI: 10.5281/zenodo.18771916
Cited by: 0

Abstract

Semaglutide has been shown to lower the incidence of cardiovascular events in non-diabetic individuals, particularly those who are overweight or obese, according to recent trials and meta-analyses.

Fields of Study & Subjects

Diabetes Treatment and Management Diabetes Cardiovascular Risks and Lipoproteins Pharmacology and Obesity Treatment

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 February 2026
Language
EN